It is also notable that bromocriptine, a dopaminergic agent that also raises endogenous levels of GLP-1 [102], is one of the few medications to show promise in enhancing levels of awareness in chronic DOC [103], which further underscores the need to more carefully study the potential role of incretin-based drugs in DOC treatment. This evidence concerns the gene GLP1R and ichthyosis.